List of Excipients in Branded Drug CLINOLIPID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Corporation	CLINOLIPID	olive oil and soybean oil	0338-9540	EGG PHOSPHOLIPIDS	2027-04-24
Baxter Healthcare Corporation	CLINOLIPID	olive oil and soybean oil	0338-9540	GLYCERIN	2027-04-24
Baxter Healthcare Corporation	CLINOLIPID	olive oil and soybean oil	0338-9540	SODIUM OLEATE	2027-04-24

Clinolipid Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Clinolipid is a 20% lipid injectable emulsion used as a source of calories and essential fatty acids in adults requiring parenteral nutrition. Its formulation combines olive oil and soybean oil with egg phospholipids, glycerin, sodium oleate, and water for injection. The commercial opportunity is strongest in formulation differentiation, ready-to-use parenteral nutrition, oxidation control, container systems, and hospital supply economics rather than in a new-molecule patent strategy.

What is Clinolipid and how is it formulated?

Clinolipid is an intravenous lipid injectable emulsion containing 200 mg of total lipid per milliliter. The lipid phase is composed primarily of olive oil and soybean oil. The product is supplied as a sterile, nonpyrogenic emulsion for intravenous administration as part of parenteral nutrition. The FDA-approved indication covers adults who require parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. [1]

Formulation component	Function in Clinolipid
Olive oil	Primary lipid source; supplies long-chain triglycerides and oleic acid
Soybean oil	Supplies essential fatty acids, including linoleic and alpha-linolenic acids
Egg phospholipids	Emulsifier that stabilizes the oil-in-water emulsion
Glycerin	Tonicity agent
Sodium oleate	Co-emulsifier and emulsion-stability aid
Water for injection	Continuous aqueous phase

Clinolipid provides approximately 2 kcal per milliliter. A 100 mL dose therefore provides about 200 kcal, while a 500 mL container provides about 1,000 kcal before accounting for other parenteral nutrition components. The formulation contains no antimicrobial preservative. [1]

The product’s excipient profile creates both regulatory constraints and commercial opportunities. Egg phospholipids introduce a clinically relevant allergy consideration. Soybean oil creates another labeling and supply-chain issue. The unsaturated oil phase requires control of oxidation, peroxide formation, headspace oxygen, light exposure, and container compatibility.

What excipients protect the performance of Clinolipid?

The excipient system is central to product performance because Clinolipid is an oil-in-water emulsion rather than a simple aqueous injection.

Egg phospholipids

Egg phospholipids provide the principal interfacial barrier around the oil droplets. Their amphiphilic structure reduces interfacial tension and helps prevent coalescence during storage and infusion.

The commercial disadvantages are regulatory and clinical:

• Egg-derived material creates a contraindication or warning risk for patients with relevant hypersensitivity.
• Natural-source phospholipids introduce batch-to-batch compositional variability.
• Phospholipid oxidation can affect emulsion stability and product quality.
• Supplier qualification must cover allergen controls, microbial controls, residual solvents, and lipid oxidation.

A replacement emulsifier could create a differentiated product if it preserves droplet-size distribution, infusion safety, sterility, and long-term physical stability. Candidate systems include synthetic phospholipids, hydrogenated phospholipids, nonionic surfactants, and mixed emulsifier systems. Each alternative would require a substantial comparability package because changes in surface chemistry can alter biodistribution, tolerability, particle-size growth, and complement activation.

Glycerin

Glycerin adjusts tonicity and contributes to the product’s osmolality. A change in glycerin concentration can affect venous tolerability, compatibility with other parenteral nutrition components, and the amount of free water delivered to the patient.

A commercial formulation strategy could use an alternative tonicity system, but the product would need to maintain acceptable osmolality and avoid precipitation or phase instability after admixture with amino acids, dextrose, electrolytes, vitamins, and trace elements.

Sodium oleate

Sodium oleate acts as a co-emulsifier. It supports interfacial stabilization but also adds a formulation variable that can affect pH, ionic strength, and compatibility with multicomponent parenteral nutrition.

A reduced-sodium formulation could have commercial value for selected patients, but the sodium contribution of the lipid emulsion is small relative to the broader parenteral nutrition regimen. The stronger opportunity is a reformulated product with improved stability after admixture rather than a sodium reduction alone.

Water for injection and the oil phase

The aqueous phase must meet injectable-water specifications. The oil phase requires control of:

• Peroxide value
• Anisidine value
• Free fatty acids
• Trace metals
• Residual moisture
• Fatty-acid composition
• Microbial and particulate contamination

Oil selection also affects clinical positioning. Olive oil is relatively rich in oleic acid and is less polyunsaturated than soybean oil. Soybean oil remains important because it supplies essential fatty acids. A product that changes the ratio of the two oils would need to demonstrate nutritional adequacy, stability, and clinical comparability.

What FDA status and exclusivity apply to Clinolipid?

Clinolipid was approved by FDA under NDA 022484 as a prescription lipid injectable emulsion. It is regulated as a drug product, not as a biologic. FDA labeling identifies the formulation, administration requirements, warnings, contraindications, and monitoring parameters. [1]

Regulatory issue	Clinolipid position
FDA pathway	NDA approval
Product type	Lipid injectable emulsion
Active formulation	20% intravenous lipid emulsion
Primary use	Adult parenteral nutrition
Biologic status	Not a biologic; no biosimilar pathway
Preservative status	No antimicrobial preservative
Orange Book relevance	Drug-product listing and any associated patent or exclusivity information must be verified against the current FDA Orange Book
Likely generic pathway	ANDA or 505(b)(2), depending on formulation and product differences

Clinolipid does not present the same exclusivity profile as a new chemical entity. Its commercial protection is more likely to depend on formulation know-how, manufacturing controls, product quality, hospital contracting, and supply reliability than on long-lived composition-of-matter protection.

A generic or follow-on applicant would need to address the product’s pharmaceutical equivalence, emulsion characteristics, sterility, container closure, labeling, and nutritional performance. For injectable emulsions, sameness is more complex than matching the nominal 20% lipid concentration.

What patents protect Clinolipid and how strong is the patent estate?

The key patent question is whether current Orange Book records identify unexpired patents for Clinolipid’s NDA. A definitive patent-expiration analysis requires the current Orange Book patent listing and relevant FDA regulatory correspondence. The public prescribing information establishes the formulation and approval basis but does not itself establish a complete patent estate. [1]

The likely protection profile is as follows:

Protection category	Relevance to Clinolipid
Composition-of-matter patent	Limited opportunity because the major oils and excipients are established pharmaceutical materials
Formulation patent	Possible protection for defined oil ratios, emulsifier systems, droplet size, or stability characteristics
Method-of-use patent	Possible claims for specific parenteral nutrition populations or administration regimens
Manufacturing patent	Potential claims covering homogenization, oxygen control, sterilization, or filling
Container patent	Potential claims covering multilayer bags, oxygen barriers, and light protection
Trade secret	Important for process parameters, raw-material specifications, and stability controls

The strongest defensible intellectual property for a Clinolipid-type product would likely come from a combination of narrowly defined formulation claims and manufacturing claims. Broad claims covering olive oil, soybean oil, egg phospholipids, glycerin, and sodium oleate would face substantial prior-art exposure because these ingredients have long been used in parenteral lipid emulsions.

Formulation patents

Potential formulation claim elements include:

• A specified olive-oil-to-soybean-oil ratio
• A defined phospholipid concentration
• A controlled mean droplet diameter
• A limited fraction of large-diameter fat globules
• Defined peroxide and anisidine values at release and shelf life
• Improved stability after admixture with dextrose and amino acids
• Reduced free-oil formation after agitation or temperature cycling
• A preservative-free formulation with a specified container closure

These claims are technically meaningful only if supported by comparative data. A patent application would be stronger if it linked a specific excipient ratio or process condition to a measurable benefit, such as reduced droplet growth, lower oxidation, improved admixture stability, or lower infusion-related adverse events.

Method-of-use patents

Method-of-use protection could address:

• Adult parenteral nutrition in patients with impaired enteral tolerance
• Use in patients requiring reduced polyunsaturated fatty-acid exposure
• Use in defined intensive-care or postoperative populations
• Dosing regimens based on triglyceride monitoring
• Administration through peripheral versus central venous access

Such patents would have limited commercial value if the product is routinely used as a general calorie and essential-fatty-acid source. They would be more valuable if tied to a clinically differentiated patient population and supported by prospective evidence.

When does Clinolipid lose exclusivity and when can generics enter?

Clinolipid’s practical exclusivity depends on three separate factors: statutory regulatory exclusivity, listed patents, and the technical difficulty of developing an equivalent injectable emulsion.

A generic applicant may pursue an ANDA if it can demonstrate the required equivalence to the reference product. A 505(b)(2) applicant may be appropriate where the proposed product differs in formulation, concentration, excipients, route details, or clinical positioning but relies partly on FDA findings for the reference product.

Paragraph IV challenges

A Paragraph IV certification would be relevant if the Orange Book lists an unexpired patent for the reference product. The challenger would assert that the patent is invalid, unenforceable, or not infringed. A patent owner could then bring infringement litigation within the statutory period, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework.

For an injectable emulsion, a Paragraph IV case could focus on:

• Whether the proposed oil ratio falls within a composition claim
• Whether the proposed droplet-size profile meets a claim limitation
• Whether process claims are infringed
• Whether container or oxygen-control claims are infringed
• Whether the patent is enabled across the full claim scope
• Whether prior lipid emulsions anticipate the claimed formulation

The litigation risk is lower when a follow-on applicant uses a materially different emulsifier system, oil ratio, or container technology. The regulatory burden rises at the same time because meaningful formulation changes can require additional clinical, compatibility, or safety data.

What biosimilar and generic risks affect Clinolipid?

Clinolipid has no biosimilar risk because it is not a biologic. The relevant competitive threat is from generic or alternative lipid injectable emulsions.

Competitor type	Competitive risk
Generic equivalent lipid emulsion	Price erosion and hospital formulary substitution
Olive-oil/soybean-oil alternative	Direct clinical and procurement competition
Soybean-oil lipid emulsion	Lower-cost calorie and essential-fatty-acid supply
Fish-oil-containing emulsion	Clinical differentiation based on fatty-acid profile
Mixed-oil emulsion	Potential positioning around inflammation, tolerability, or fatty-acid balance
Compounded parenteral nutrition	Local price and supply competition, subject to compounding controls
Ready-to-use multi-chamber nutrition bag	Workflow and labor savings that can displace standalone lipid products

The main generic-entry barriers are manufacturing complexity, sterile injectable compliance, raw-material qualification, emulsion characterization, and hospital purchasing requirements. These barriers can delay entry even when formal patent protection is limited.

What excipient strategies create the best commercial opportunities?

Oxidation-control strategy

A differentiated product could target lower oxidation throughout shelf life and administration. The strategy could combine:

• Lower-peroxide raw oils
• Chelation of trace metals
• Nitrogen overlay or reduced-oxygen headspace
• Oxygen-barrier container films
• Light-protective packaging
• Optimized sterilization and filling conditions
• Antioxidant systems, where permitted and clinically acceptable

Any antioxidant excipient would require careful assessment of injectable safety, compatibility, labeling, and regulatory precedent.

Alternative emulsifier strategy

Replacing egg phospholipids could reduce allergen concerns and create a product claim around synthetic or non-animal-derived excipients. The development risk is high because the emulsifier controls droplet stability and may influence biological interactions.

The strongest opportunity is a formulation that demonstrates equivalent nutritional delivery with:

• Lower allergen burden
• Lower batch variability
• Better thermal stability
• Longer shelf life
• Improved compatibility with total parenteral nutrition admixtures

Fish-oil and mixed-oil strategy

Adding fish oil or using a structured mixed-oil system could position the product against conventional soybean- and olive-oil emulsions. Potential components include medium-chain triglycerides, fish oil, olive oil, and soybean oil.

The commercial claims would need to remain within supported nutritional and regulatory boundaries. A differentiated fatty-acid profile alone may not justify premium pricing unless it produces measurable clinical or operational benefits.

Container and delivery strategy

The container is a major commercial lever. Opportunities include:

• Multi-layer oxygen-barrier bags
• Reduced extractables and leachables
• Light-resistant overwraps
• Ready-to-use single-dose containers
• Larger institutional containers
• Compatibility with automated compounding systems
• Port designs that reduce microbial entry and dosing errors

A container patent may be more defensible than a broad excipient patent if it links material selection to reduced oxidation or improved shelf life.

How does Clinolipid compare with competing lipid emulsions?

Product strategy	Lipid profile	Commercial positioning
Clinolipid-type formulation	Olive oil and soybean oil	Balanced long-chain lipid emulsion with established hospital use
Soybean-oil emulsion	Predominantly soybean oil	Cost-oriented conventional parenteral nutrition
Fish-oil emulsion	Fish oil or fish-oil dominant	Specialized fatty-acid profile and clinical differentiation
Mixed-oil emulsion	Soybean, medium-chain triglyceride, olive, and fish oils	Broader lipid profile and premium positioning
Compounded lipid admixture	Variable	Institutional flexibility, with greater quality-control burden

Clinolipid’s commercial position depends on more than fatty-acid composition. Hospitals evaluate acquisition cost, product availability, nursing workflow, compatibility, waste, storage, adverse-event experience, and supplier reliability.

What litigation, licensing, and manufacturing barriers matter?

No material Clinolipid-specific patent litigation or licensing transaction can be established from the FDA prescribing information alone. Commercial diligence should distinguish between:

1. Patents listed for the reference product.
2. Patents owned by the manufacturer but not listed in the Orange Book.
3. Third-party patents covering lipid emulsions, containers, or manufacturing.
4. Trade secrets that are not discoverable through patent databases.
5. Hospital contracts and supply agreements that affect market access.

Manufacturing is a meaningful barrier. The critical process steps include oil blending, aqueous-phase preparation, emulsification, homogenization, sterilization, aseptic filling, and container closure. Process control must maintain droplet-size specifications and prevent phase separation, oxidation, microbial contamination, and particulate formation.

The most valuable manufacturing IP would cover reproducible emulsion formation at commercial scale, low-oxygen processing, improved sterilization compatibility, and extended stability after admixture.

What revenue exposure and launch scenarios apply to Clinolipid?

Clinolipid revenue is exposed to three main events:

• Price erosion from generic or follow-on lipid emulsions
• Formulary displacement by alternative mixed-oil products
• Supply disruption that shifts hospitals to competing products

A generic launch would likely produce a staged impact rather than immediate full substitution. Hospitals may retain the reference product for selected patients while using lower-cost alternatives for routine parenteral nutrition. The pace would depend on therapeutic interchange policies, contracts, shortage conditions, and whether the entrant matches the reference product’s container sizes and administration instructions.

A premium reformulation could command better economics if it offers a clear hospital benefit, such as reduced wastage, longer in-use stability, improved oxygen protection, fewer preparation steps, or compatibility with automated compounding equipment.

Geographic expansion would require country-specific review of excipient acceptability, allergen labeling, parenteral nutrition standards, container requirements, and reimbursement. FDA approval does not establish market authorization in Europe, Canada, Japan, or other jurisdictions.

Key Takeaways

• Clinolipid is a 20% intravenous lipid injectable emulsion based on olive oil and soybean oil.
• Egg phospholipids, glycerin, sodium oleate, and water for injection are central to product performance.
• The strongest commercial opportunities are in oxidation control, non-animal emulsifiers, mixed-oil systems, container technology, and ready-to-use parenteral nutrition.
• Clinolipid has no biosimilar risk because it is not a biologic.
• Generic competition is technically feasible but requires complex injectable-emulsion development and manufacturing controls.
• Broad composition patents are likely less defensible than focused claims covering stability, droplet size, admixture compatibility, manufacturing, and packaging.
• Orange Book patent status and any Paragraph IV exposure must be assessed using current FDA patent-listing data.
• Hospital economics will depend on acquisition cost, supply reliability, workflow, container compatibility, and formulary policy.

FAQs

Is Clinolipid an active pharmaceutical ingredient or a finished drug product?

Clinolipid is a finished drug product. Its therapeutic and nutritional effect comes from the lipid mixture, while the phospholipids, glycerin, sodium oleate, and water function as formulation excipients.

Can egg phospholipids in Clinolipid be replaced?

They can potentially be replaced, but a substitute emulsifier would require extensive testing for droplet size, stability, sterility, compatibility, infusion safety, and biological performance.

Is a fish-oil version of Clinolipid a biosimilar?

No. A fish-oil or mixed-oil lipid emulsion would be a different drug product and could require an ANDA, 505(b)(2) application, or full NDA pathway depending on the formulation and regulatory strategy.

What is the most valuable patent claim for a Clinolipid-type product?

A claim that connects a defined excipient or process range to a measurable benefit, such as lower oxidation, improved admixture stability, controlled droplet size, or extended shelf life, is likely more commercially defensible than a broad claim covering conventional lipid-emulsion ingredients.

Can Clinolipid be compounded with other parenteral nutrition components?

Clinolipid is used as part of parenteral nutrition, but admixture compatibility, order of mixing, storage, infusion conditions, and stability must follow the approved labeling and institutional procedures. [1]

References

1. U.S. Food and Drug Administration. (2023). Clinolipid (lipid injectable emulsion), prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Pharmacopeia. (2024). General chapter <729> globule size distribution in lipid injectable emulsions. United States Pharmacopeial Convention. https://www.usp.org/

4. U.S. Food and Drug Administration. (2019). Drug products containing parenteral nutrition components: Regulatory and quality considerations. FDA. https://www.fda.gov/drugs

5. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-guidance-documents